Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells
Open Access
- 1 April 2025
- journal article
- review article
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Abstract
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.Keywords
Funding Information
- the CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-B-063)
- Beijing Hope Run Special Fund of Cancer Foundation of China (LC2022B18)
- National Natural Science Foundation of China (82072803)
- National Natural Science Foundation of China (82103231)
- National Natural Science Foundation of China (82472722)
This publication has 105 references indexed in Scilit:
- Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Mechanisms Underlying UbiquitinationAnnual Review of Biochemistry, 2001
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote ChromosomeCell, 1999
- p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agentsOncogene, 1998
- THE UBIQUITIN SYSTEMAnnual Review of Biochemistry, 1998
- Wild-type p53 suppresses transcription of the human O-6-methylguanine-DNA methyltransferase gene1996
- Ubiquitination-Dependent Proteolysis of O6-Methylguanine-DNA Methyltransferase in Human and Murine Tumor Cells following Inactivation with O6-Benzylguanine or 1,3-Bis(2-chloroethyl)-1-nitrosoureaBiochemistry, 1996
- Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.1990